Cookie Settings

We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .


These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name Webedition CMS
Purpose This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name econda
Purpose Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.

These cookies help us understand how visitors interact with our website by collecting and analyzing information anonymously. Depending on the tool, one or more cookies are set by the provider.

Name econda
Purpose Statistics
External media

Content from external media platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name YouTube
Purpose Show YouTube content
Name Twitter
Purpose activate Twitter Feeds

Division of Applied Bioinformatics

Prof. Dr. Benedikt Brors


The availability of methods like next-generation sequencing, which allows one to interrogate all bases of the human genome and detect somatic mutations in cancer with unprecedented precision, have provided a basis to understand the genetic causes of cancer on the systems level. Such data have proven useful to select individual therapy strategies, in particular targeted cancer drugs and immunotherapeutics. However, the high-dimensional nature of such data requires sophisticated computational approaches for their analysis and for supporting medical decision making. The major aim of the division is to develop and apply such computational methods to better understand cancer initiation and progression, and to improve cancer care by predicting which drugs will work to combat an individual tumor. For this, we develop automated pipelines to detect different classes of genetic alterations in cancer, and link this to sensitivities to approved cancer drugs. We further aim to understand mutations in the non-coding part of the genome and to characterize cancer evolution and heterogeneity. We have contributed to several projects in the International Cancer Genome Consortium, to elucidate the genetic landscapes of, e.g., medulloblastoma, early-onset prostate cancer and malignant B-cell lymphoma.

We are part of the Pan Cancer Analysis of Whole Genomes Project as well as the German Epigenetics Project, DEEP. We are systematically exploring epigenetic and genetic alterations in cancer outside of protein-coding genes, and aim to understand their regulatory consequences. We perform bioinformatic analysis for a number of precision oncology trials in the German Cancer Consortium (DKTK) and the National Center of Tumor Diseases, e.g. DKTK-MASTER, INFORM and N2M2. Current research also aims to integrate data from high-throughput screening experiments in cancer cell lines and xenografts, as well as to understand genetic alterations on the network level. We are involved in initiatives on genomic data sharing and integration with clinical and radiological data.

We are part of three different research networks within the International Cancer Genome Consortium (ICGC):

We also contribute to the ICGC project on Pan Cancer Analysis of Whole Genomes.


Prof. Dr. Benedikt Brors
Applied Bioinformatics (B330)

Berliner Str. 41
(walk-in address)
69120 Heidelberg
Tel: +49 6221 / 42 3728
Fax: +49 6221 / 42 3626

PA/Secretary: Corinna Sprengart

Selected Publications

  • Horak P, Heining C, Kreutzfeldt S, Hutter B, Mock A, Hüllein J, Fröhlich M, Uhrig S, (…),Brors B, Stenzinger A, Schröck E, Hübschmann D, Weichert W, Glimm H, Fröhling S. Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare Cancers. Cancer Discov. 11(11):2780-2795 (2021).
  • Delacher M, Simon M, Sanderink L, (…), Brors B, Imbusch CD, Feuerer M. Single-cell chromatin accessibility landscape identifies tissue repair program in human regulatory T cells. Immunity. 54(4):702-720.e17 (2021)
  • ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium. Pan-cancer analysis of whole genomes. Nature.578(7793):82-93 (2020).
  • Sieverling L, Hong C, Koser SD, Ginsbach P, Kleinheinz K, Hutter B, (…), PCAWG-Structural Variation Working Group; Brors B, Rippe K, Jones DTW, Feuerbach L; PCAWG Consortium. Genomic footprints of activated telomere maintenance mechanisms in cancer. Nat Commun.11(1):733 (2020).
to top
powered by webEdition CMS